Telix Pharmaceuticals Limited Stock Performance
| TLX Stock | 18.30 0.06 0.33% |
On a scale of 0 to 100, Telix Pharmaceuticals holds a performance score of 5. The entity has a beta of 0.22, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Telix Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Telix Pharmaceuticals is expected to be smaller as well. Please check Telix Pharmaceuticals' value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Telix Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Telix Pharmaceuticals Limited are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile essential indicators, Telix Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.65) | Five Day Return (2.39) | Year To Date Return 22.4 | Ten Year Return 21.19 | All Time Return 21.19 |
1 | Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics ... | 01/30/2025 |
2 | Telix 2024 Full Year Results Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to 1.23 Billion | 02/20/2025 |
3 | Recruitment Spotlight Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami | 02/25/2025 |
4 | Investor Webinar Telix Therapeutics Urology Showcase and Expert Forum | 03/03/2025 |
5 | Health Check Half-price sale as brokers ring the bell on Neuren shares | 03/04/2025 |
6 | Acquisition by Liss Victor S of tradable shares of Telix Pharmaceuticals at 9.0 subject to Rule 16b-3 | 03/07/2025 |
7 | Up 136 percent in a year, why is this ASX 200 share slipping on Wednesday | 03/11/2025 |
8 | Illuccix Approved for Prostate Cancer Imaging in BrazilFirst | 03/17/2025 |
9 | Health Check Fantastico Telix wins Brazilian assent for prostate cancer imaging agent | 03/18/2025 |
10 | FDA Approves New Prostate Cancer Imaging Agent Gozellix | 03/21/2025 |
11 | Health Check Optheas solvency in question after monumental phase III eye disease trial failure | 03/24/2025 |
| Begin Period Cash Flow | 123.2 M |
Telix |
Telix Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,646 in Telix Pharmaceuticals Limited on December 26, 2024 and sell it today you would earn a total of 184.00 from holding Telix Pharmaceuticals Limited or generate 11.18% return on investment over 90 days. Telix Pharmaceuticals Limited is generating 0.2255% of daily returns assuming volatility of 3.2666% on return distribution over 90 days investment horizon. In other words, 29% of stocks are less volatile than Telix, and above 96% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Telix Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telix Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Telix Pharmaceuticals Limited, and traders can use it to determine the average amount a Telix Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.069
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TLX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.27 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Telix Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telix Pharmaceuticals by adding it to a well-diversified portfolio.
Telix Pharmaceuticals Fundamentals Growth
Telix Stock prices reflect investors' perceptions of the future prospects and financial health of Telix Pharmaceuticals, and Telix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telix Stock performance.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.0797 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 5.2 B | ||||
| Shares Outstanding | 334.72 M | ||||
| Price To Book | 20.71 X | ||||
| Price To Sales | 8.09 X | ||||
| Revenue | 783.21 M | ||||
| Gross Profit | 405.35 M | ||||
| EBITDA | 92.55 M | ||||
| Net Income | 49.92 M | ||||
| Total Debt | 581.45 M | ||||
| Book Value Per Share | 1.21 X | ||||
| Earnings Per Share | 0.09 X | ||||
| Market Capitalization | 5.23 B | ||||
| Total Asset | 1.52 B | ||||
| Retained Earnings | (212.96 M) | ||||
| Working Capital | 587.65 M | ||||
About Telix Pharmaceuticals Performance
Evaluating Telix Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Telix Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Telix Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 50.90 | 65.25 | |
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.09 | 0.09 |
Things to note about Telix Pharmaceuticals performance evaluation
Checking the ongoing alerts about Telix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Telix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telix Pharmaceuticals had very high historical volatility over the last 90 days | |
| Telix Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Telix Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from stockhead.com.au: Health Check Optheas solvency in question after monumental phase III eye disease trial failure |
- Analyzing Telix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Telix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telix Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telix Pharmaceuticals' stock. These opinions can provide insight into Telix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.